Capital Research Global Investors
GEVA

Capital Research Global Investors’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Capital Research Global Investors’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-4,527,358
Closed -$442M – 462
2015
Q1 		$442M Buy
4,527,358
+458,100
+11% +$48.5M 0.15% 142
2014
Q4 		$378M Buy
4,069,258
+6,486
+0.2% +$512K 0.13% 175
2014
Q3 		$279M Buy
4,062,772
+18,011
+0.4% +$1.29M 0.1% 197
2014
Q2 		$424M Buy
4,044,761
+10,124
+0.3% +$861K 0.15% 144
2014
Q1 		$335M Buy
4,034,637
+269,214
+7% +$24.9M 0.12% 170
2013
Q4 		$244M Buy
3,765,423
+249,651
+7% +$14.8M 0.09% 199
2013
Q3 		$223M Buy
3,515,772
+193,970
+6% +$9.55M 0.09% 206
2013
Q2 		$140M Buy
+3,321,802
New +$151M 0.06% 238

Capital Research Global Investors's GEVA Position: Q2 2015 in Review

Capital Research Global Investors sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 4,527,358 shares — an estimated $442M sold.

Capital Research Global Investors first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $442M in Q1 2015. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

  • Capital Research Global Investors reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • Capital Research Global Investors sold 4,527,358 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $442M.
  • Capital Research Global Investors first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
  • Capital Research Global Investors's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $442M in Q1 2015.
  • 0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on Capital Research Global Investors's 13F filing for Q2 2015, filed 14 Aug 2015.